The LAMEA Agentic AI In Pharmaceuticals Market is expected to reach USD 45.33 million by 2033, growing at a CAGR of 40% during 2026-2033.
The Brazil and Saudi Arabia led the LAMEA Agentic AI In Pharmaceuticals Market by Country with a market share of 24.8% and 15.9% in 2025.The UAE market is expected to witness a CAGR of 38.6% during throughout the forecast period.
The LAMEA (Latin America, Middle East, and Africa) Agentic AI in Pharmaceuticals Market is witnessing significant growth driven by the convergence of autonomous artificial intelligence technologies with pharmaceutical research, drug development, clinical trials, and manufacturing operations. Initially, AI adoption across LAMEA pharmaceutical ecosystems was limited to predictive analytics and data automation; however, advancements in machine learning, natural language processing, and autonomous AI agents have transformed pharmaceutical workflows by enabling independent decision-making, adaptive experimentation, and intelligent process optimization.
Several transformative trends are shaping market development. Regulatory bodies across LAMEA are gradually introducing AI governance frameworks that support safe and transparent deployment of autonomous AI systems. Cross-border healthcare data collaboration is expanding the availability of diverse datasets, improving AI model accuracy and enabling more personalized therapeutics. Additionally, increasing automation of clinical trial management and pharmaceutical manufacturing is reducing development costs while accelerating time-to-market for new therapies. These developments are positioning agentic AI as a strategic enabler of pharmaceutical innovation across the region.
End User Outlook
Based on End User, the market is segmented into Large Pharmaceutical Companies, Small and Mid-Size Biotech Firms, Contract Research Organizations, and Academic and Research Institutes.
The Large Pharmaceutical Companies segment accounted for the largest revenue share in 2025 due to growing investments in AI-powered drug discovery, clinical development optimization, and pharmaceutical manufacturing automation. The Small and Mid-Size Biotech Firms segment recorded strong growth supported by increasing adoption of cloud-based AI research platforms and advanced drug discovery technologies. The Contract Research Organizations (CROs) segment benefited from rising demand for outsourced pharmaceutical research and AI-enabled clinical trial management solutions. Meanwhile, the Academic and Research Institutes segment witnessed steady expansion driven by increasing utilization of AI-powered scientific research platforms and biomedical innovation initiatives throughout the region.
Deployment Mode Outlook
Based on Deployment Mode, the market is segmented into Cloud-Based, Hybrid, and On-Premise.
The Cloud-Based segment held the highest revenue share in 2025 owing to increasing demand for scalable computing infrastructure, collaborative research environments, and cost-efficient AI deployment. The Hybrid segment demonstrated significant growth as pharmaceutical organizations sought to balance cloud scalability with enhanced security and compliance capabilities. The On-Premise segment maintained a notable market presence among organizations prioritizing data privacy, intellectual property protection, and direct control over pharmaceutical research infrastructure.
Application Outlook
Based on Application, the market is segmented into Clinical-Trial Design and Recruitment, Drug Discovery and Lead Identification, Lead Optimization, Pharmacovigilance and Safety Monitoring, Pre-clinical Development, Manufacturing-Process Optimization, and Other Applications.
The Clinical-Trial Design and Recruitment market dominated the LAMEA Agentic AI In Pharmaceuticals Market by Application in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 13.41 million by 2029, growing at a CAGR of 37.9% during the forecast period. The Drug Discovery and Lead Identification market is expected to witness a CAGR of 38.7% during 2026-2033.
The Pharmacovigilance and Safety Monitoring segment expanded as pharmaceutical companies increasingly adopted AI-driven adverse event detection and regulatory reporting systems. Additionally, the Pre-clinical Development, Manufacturing-Process Optimization, and Other Applications segments witnessed increasing adoption as organizations accelerated pharmaceutical digital transformation initiatives.
Country Outlook
Based on Country, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The Brazil market dominated the LAMEA Agentic AI In Pharmaceuticals Market by country in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 10.71 million by 2029, growing at a CAGR of 38.2% during the forecast period. The Argentina market is expected to witness a CAGR of 40.4% during 2026-2033.
Brazil emerged as the leading market in 2025, supported by expanding pharmaceutical research activities, increasing adoption of AI-powered drug discovery platforms, and growing government support for healthcare innovation. The UAE and Saudi Arabia are witnessing rapid growth due to strong investments in artificial intelligence, healthcare modernization programs, and pharmaceutical digital transformation initiatives.
List of Key Companies Profiled
By End User
The Brazil and Saudi Arabia led the LAMEA Agentic AI In Pharmaceuticals Market by Country with a market share of 24.8% and 15.9% in 2025.The UAE market is expected to witness a CAGR of 38.6% during throughout the forecast period.
The LAMEA (Latin America, Middle East, and Africa) Agentic AI in Pharmaceuticals Market is witnessing significant growth driven by the convergence of autonomous artificial intelligence technologies with pharmaceutical research, drug development, clinical trials, and manufacturing operations. Initially, AI adoption across LAMEA pharmaceutical ecosystems was limited to predictive analytics and data automation; however, advancements in machine learning, natural language processing, and autonomous AI agents have transformed pharmaceutical workflows by enabling independent decision-making, adaptive experimentation, and intelligent process optimization.
Several transformative trends are shaping market development. Regulatory bodies across LAMEA are gradually introducing AI governance frameworks that support safe and transparent deployment of autonomous AI systems. Cross-border healthcare data collaboration is expanding the availability of diverse datasets, improving AI model accuracy and enabling more personalized therapeutics. Additionally, increasing automation of clinical trial management and pharmaceutical manufacturing is reducing development costs while accelerating time-to-market for new therapies. These developments are positioning agentic AI as a strategic enabler of pharmaceutical innovation across the region.
End User Outlook
Based on End User, the market is segmented into Large Pharmaceutical Companies, Small and Mid-Size Biotech Firms, Contract Research Organizations, and Academic and Research Institutes.
The Large Pharmaceutical Companies segment accounted for the largest revenue share in 2025 due to growing investments in AI-powered drug discovery, clinical development optimization, and pharmaceutical manufacturing automation. The Small and Mid-Size Biotech Firms segment recorded strong growth supported by increasing adoption of cloud-based AI research platforms and advanced drug discovery technologies. The Contract Research Organizations (CROs) segment benefited from rising demand for outsourced pharmaceutical research and AI-enabled clinical trial management solutions. Meanwhile, the Academic and Research Institutes segment witnessed steady expansion driven by increasing utilization of AI-powered scientific research platforms and biomedical innovation initiatives throughout the region.
Deployment Mode Outlook
Based on Deployment Mode, the market is segmented into Cloud-Based, Hybrid, and On-Premise.
The Cloud-Based segment held the highest revenue share in 2025 owing to increasing demand for scalable computing infrastructure, collaborative research environments, and cost-efficient AI deployment. The Hybrid segment demonstrated significant growth as pharmaceutical organizations sought to balance cloud scalability with enhanced security and compliance capabilities. The On-Premise segment maintained a notable market presence among organizations prioritizing data privacy, intellectual property protection, and direct control over pharmaceutical research infrastructure.
Application Outlook
Based on Application, the market is segmented into Clinical-Trial Design and Recruitment, Drug Discovery and Lead Identification, Lead Optimization, Pharmacovigilance and Safety Monitoring, Pre-clinical Development, Manufacturing-Process Optimization, and Other Applications.
The Clinical-Trial Design and Recruitment market dominated the LAMEA Agentic AI In Pharmaceuticals Market by Application in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 13.41 million by 2029, growing at a CAGR of 37.9% during the forecast period. The Drug Discovery and Lead Identification market is expected to witness a CAGR of 38.7% during 2026-2033.
The Pharmacovigilance and Safety Monitoring segment expanded as pharmaceutical companies increasingly adopted AI-driven adverse event detection and regulatory reporting systems. Additionally, the Pre-clinical Development, Manufacturing-Process Optimization, and Other Applications segments witnessed increasing adoption as organizations accelerated pharmaceutical digital transformation initiatives.
Country Outlook
Based on Country, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The Brazil market dominated the LAMEA Agentic AI In Pharmaceuticals Market by country in 2025, and is expected to continue to be a dominant market till 2033; thereby, achieving a market value of USD 10.71 million by 2029, growing at a CAGR of 38.2% during the forecast period. The Argentina market is expected to witness a CAGR of 40.4% during 2026-2033.
Brazil emerged as the leading market in 2025, supported by expanding pharmaceutical research activities, increasing adoption of AI-powered drug discovery platforms, and growing government support for healthcare innovation. The UAE and Saudi Arabia are witnessing rapid growth due to strong investments in artificial intelligence, healthcare modernization programs, and pharmaceutical digital transformation initiatives.
List of Key Companies Profiled
- InSilico Medicine
- Numerion Labs, Inc.
- BenevolentAI Group
- Shenzhen Jingtai Technology Co., Ltd. (XtalPi)
- Recursion Pharmaceuticals, Inc.
- Deep Genomics Incorporated
- Schrödinger, LLC
- Owkin Inc.
- PeptiDream Inc.
- Healx Limited
By End User
- Large Pharmaceutical Companies
- Small and Mid-Size Biotech Firms
- Contract Research Organizations
- Academic and Research Institutes
- Cloud-Based
- Hybrid
- On-Premise
- Clinical-Trial Design and Recruitment
- Drug Discovery and Lead Identification
- Lead Optimization
- Pharmacovigilance and Safety Monitoring
- Pre-clinical Development
- Manufacturing-Process Optimization
- Other Application
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Table of Contents
Chapter 1. LAMEA Market1.1 Market Overview
1.2 Key Factors Impacting Market
1.2.1 Market Drivers
1.2.2 Market Restraints
1.2.3 Market Opportunities
1.2.4 Market Challenges
1.2.5 Market Trends
1.2.6 State of Competition
1.2.7 Market Consolidation
1.2.8 Key Customer Criteria
1.3 Product Life Cycle
1.4 Segmentation By End User
1.4.1 Large Pharmaceutical Companies
1.4.2 Small and Mid-Size Biotech Firms
1.4.3 Contract Research Organizations
1.4.4 Academic and Research Institutes
1.5 Segmentation By Deployment Mode
1.5.1 Cloud-Based
1.5.2 Hybrid
1.5.3 On-Premise
1.6 Segmentation By Application
1.6.1 Clinical-Trial Design and Recruitment
1.6.2 Drug Discovery and Lead Identification
1.6.3 Lead Optimization
1.6.4 Pharmacovigilance and Safety Monitoring
1.6.5 Pre-clinical Development
1.6.6 Manufacturing-Process Optimization
1.6.7 Other Application
1.7 Segmentation By Country
1.7.1 Brazil
1.7.1.1 Segmentation By End User
1.7.1.1.1 Large Pharmaceutical Companies
1.7.1.1.2 Small and Mid-Size Biotech Firms
1.7.1.1.3 Contract Research Organizations
1.7.1.1.4 Academic and Research Institutes
1.7.1.2 Segmentation By Deployment Mode
1.7.1.2.1 Cloud-Based
1.7.1.2.2 Hybrid
1.7.1.2.3 On-Premise
1.7.1.3 Segmentation By Application
1.7.1.3.1 Clinical-Trial Design and Recruitment
1.7.1.3.2 Drug Discovery and Lead Identification
1.7.1.3.3 Lead Optimization
1.7.1.3.4 Pharmacovigilance and Safety Monitoring
1.7.1.3.5 Pre-clinical Development
1.7.1.3.6 Manufacturing-Process Optimization
1.7.1.3.7 Other Application
1.7.2 Argentina
1.7.2.1 Segmentation By End User
1.7.2.1.1 Large Pharmaceutical Companies
1.7.2.1.2 Small and Mid-Size Biotech Firms
1.7.2.1.3 Contract Research Organizations
1.7.2.1.4 Academic and Research Institutes
1.7.2.2 Segmentation By Deployment Mode
1.7.2.2.1 Cloud-Based
1.7.2.2.2 Hybrid
1.7.2.2.3 On-Premise
1.7.2.3 Segmentation By Application
1.7.2.3.1 Clinical-Trial Design and Recruitment
1.7.2.3.2 Drug Discovery and Lead Identification
1.7.2.3.3 Lead Optimization
1.7.2.3.4 Pharmacovigilance and Safety Monitoring
1.7.2.3.5 Pre-clinical Development
1.7.2.3.6 Manufacturing-Process Optimization
1.7.2.3.7 Other Application
1.7.3 UAE
1.7.3.1 Segmentation By End User
1.7.3.1.1 Large Pharmaceutical Companies
1.7.3.1.2 Small and Mid-Size Biotech Firms
1.7.3.1.3 Contract Research Organizations
1.7.3.1.4 Academic and Research Institutes
1.7.3.2 Segmentation By Deployment Mode
1.7.3.2.1 Cloud-Based
1.7.3.2.2 Hybrid
1.7.3.2.3 On-Premise
1.7.3.3 Segmentation By Application
1.7.3.3.1 Clinical-Trial Design and Recruitment
1.7.3.3.2 Drug Discovery and Lead Identification
1.7.3.3.3 Lead Optimization
1.7.3.3.4 Pharmacovigilance and Safety Monitoring
1.7.3.3.5 Pre-clinical Development
1.7.3.3.6 Manufacturing-Process Optimization
1.7.3.3.7 Other Application
1.7.4 Saudi Arabia
1.7.4.1 Segmentation By End User
1.7.4.1.1 Large Pharmaceutical Companies
1.7.4.1.2 Small and Mid-Size Biotech Firms
1.7.4.1.3 Contract Research Organizations
1.7.4.1.4 Academic and Research Institutes
1.7.4.2 Segmentation By Deployment Mode
1.7.4.2.1 Cloud-Based
1.7.4.2.2 Hybrid
1.7.4.2.3 On-Premise
1.7.4.3 Segmentation By Application
1.7.4.3.1 Clinical-Trial Design and Recruitment
1.7.4.3.2 Drug Discovery and Lead Identification
1.7.4.3.3 Lead Optimization
1.7.4.3.4 Pharmacovigilance and Safety Monitoring
1.7.4.3.5 Pre-clinical Development
1.7.4.3.6 Manufacturing-Process Optimization
1.7.4.3.7 Other Application
1.7.5 South Africa
1.7.5.1 Segmentation By End User
1.7.5.1.1 Large Pharmaceutical Companies
1.7.5.1.2 Small and Mid-Size Biotech Firms
1.7.5.1.3 Contract Research Organizations
1.7.5.1.4 Academic and Research Institutes
1.7.5.2 Segmentation By Deployment Mode
1.7.5.2.1 Cloud-Based
1.7.5.2.2 Hybrid
1.7.5.2.3 On-Premise
1.7.5.3 Segmentation By Application
1.7.5.3.1 Clinical-Trial Design and Recruitment
1.7.5.3.2 Drug Discovery and Lead Identification
1.7.5.3.3 Lead Optimization
1.7.5.3.4 Pharmacovigilance and Safety Monitoring
1.7.5.3.5 Pre-clinical Development
1.7.5.3.6 Manufacturing-Process Optimization
1.7.5.3.7 Other Application
1.7.6 Nigeria
1.7.6.1 Segmentation By End User
1.7.6.1.1 Large Pharmaceutical Companies
1.7.6.1.2 Small and Mid-Size Biotech Firms
1.7.6.1.3 Contract Research Organizations
1.7.6.1.4 Academic and Research Institutes
1.7.6.2 Segmentation By Deployment Mode
1.7.6.2.1 Cloud-Based
1.7.6.2.2 Hybrid
1.7.6.2.3 On-Premise
1.7.6.3 Segmentation By Application
1.7.6.3.1 Clinical-Trial Design and Recruitment
1.7.6.3.2 Drug Discovery and Lead Identification
1.7.6.3.3 Lead Optimization
1.7.6.3.4 Pharmacovigilance and Safety Monitoring
1.7.6.3.5 Pre-clinical Development
1.7.6.3.6 Manufacturing-Process Optimization
1.7.6.3.7 Other Application
1.7.7 Rest of LAMEA
1.7.7.1 Segmentation By End User
1.7.7.1.1 Large Pharmaceutical Companies
1.7.7.1.2 Small and Mid-Size Biotech Firms
1.7.7.1.3 Contract Research Organizations
1.7.7.1.4 Academic and Research Institutes
1.7.7.2 Segmentation By Deployment Mode
1.7.7.2.1 Cloud-Based
1.7.7.2.2 Hybrid
1.7.7.2.3 On-Premise
1.7.7.3 Segmentation By Application
1.7.7.3.1 Clinical-Trial Design and Recruitment
1.7.7.3.2 Drug Discovery and Lead Identification
1.7.7.3.3 Lead Optimization
1.7.7.3.4 Pharmacovigilance and Safety Monitoring
1.7.7.3.5 Pre-clinical Development
1.7.7.3.6 Manufacturing-Process Optimization
1.7.7.3.7 Other Application
Chapter 2. Company Snapshot
2.1 InSilico Medicine
2.1.1 Business Overview
2.1.2 Key Information
2.1.3 Company Focus
2.1.4 Strategic Insights
2.1.5 Strategy Deployed
2.1.6 Product & Service Portfolio
2.1.7 Capability Overview
2.1.8 Technology & Innovation Focus
2.1.9 Customers / End Users
2.1.10 Competitive Positioning
2.1.11 Key Differentiators
2.1.12 Portfolio Matrix
2.1.13 SWOT Analysis
2.1.14 Future Outlook
2.2 Numerion Labs, Inc.
2.2.1 Business Overview
2.2.2 Key Information
2.2.3 Company Focus
2.2.4 Strategic Insights
2.2.5 Strategy Deployed
2.2.6 Product & Service Portfolio
2.2.7 Capability Overview
2.2.8 Technology & Innovation Focus
2.2.9 Customers / End Users
2.2.10 Competitive Positioning
2.2.11 Key Differentiators
2.2.12 Portfolio Matrix
2.2.13 SWOT Analysis
2.2.14 Future Outlook
2.3 BenevolentAI Group
2.3.1 Business Overview
2.3.2 Key Information
2.3.3 Company Focus
2.3.4 Strategic Insights
2.3.5 Strategy Deployed
2.3.6 Product & Service Portfolio
2.3.7 Capability Overview
2.3.8 Technology & Innovation Focus
2.3.9 Customers / End Users
2.3.10 Competitive Positioning
2.3.11 Key Differentiators
2.3.12 Portfolio Matrix
2.3.13 SWOT Analysis
2.3.14 Future Outlook
2.4 Shenzhen Jingtai Technology Co., Ltd (XtalPi)
2.4.1 Business Overview
2.4.2 Key Information
2.4.3 Company Focus
2.4.4 Strategic Insights
2.4.5 Strategy Deployed
2.4.6 Product & Service Portfolio
2.4.7 Capability Overview
2.4.8 Technology & Innovation Focus
2.4.9 Customers / End Users
2.4.10 Competitive Positioning
2.4.11 Key Differentiators
2.4.12 Portfolio Matrix
2.4.13 SWOT Analysis
2.4.14 Future Outlook
2.5 Recursion Pharmaceuticals, Inc.
2.5.1 Business Overview
2.5.2 Key Information
2.5.3 Company Focus
2.5.4 Strategic Insights
2.5.5 Strategy Deployed
2.5.6 Product & Service Portfolio
2.5.7 Capability Overview
2.5.8 Technology & Innovation Focus
2.5.9 Customers / End Users
2.5.10 Competitive Positioning
2.5.11 Key Differentiators
2.5.12 Portfolio Matrix
2.5.13 SWOT Analysis
2.5.14 Future Outlook
2.6 Deep Genomics Incorporated
2.6.1 Business Overview
2.6.2 Key Information
2.6.3 Company Focus
2.6.4 Strategic Insights
2.6.5 Strategy Deployed
2.6.6 Product & Service Portfolio
2.6.7 Capability Overview
2.6.8 Technology & Innovation Focus
2.6.9 Customers / End Users
2.6.10 Competitive Positioning
2.6.11 Key Differentiators
2.6.12 Portfolio Matrix
2.6.13 SWOT Analysis
2.6.14 Future Outlook
2.7 Schrödinger, LLC
2.7.1 Business Overview
2.7.2 Key Information
2.7.3 Company Focus
2.7.4 Strategic Insights
2.7.5 Strategy Deployed
2.7.6 Product & Service Portfolio
2.7.7 Capability Overview
2.7.8 Technology & Innovation Focus
2.7.9 Customers / End Users
2.7.10 Competitive Positioning
2.7.11 Key Differentiators
2.7.12 Portfolio Matrix
2.7.13 SWOT Analysis
2.7.14 Future Outlook
2.8 Owkin Inc.
2.8.1 Business Overview
2.8.2 Key Information
2.8.3 Company Focus
2.8.4 Strategic Insights
2.8.5 Strategy Deployed
2.8.6 Product & Service Portfolio
2.8.7 Capability Overview
2.8.8 Technology & Innovation Focus
2.8.9 Customers / End Users
2.8.10 Competitive Positioning
2.8.11 Key Differentiators
2.8.12 Portfolio Matrix
2.8.13 SWOT Analysis
2.8.14 Future Outlook
2.9 PeptiDream Inc.
2.9.1 Business Overview
2.9.2 Key Information
2.9.3 Company Focus
2.9.4 Strategic Insights
2.9.5 Strategy Deployed
2.9.6 Product & Service Portfolio
2.9.7 Capability Overview
2.9.8 Technology & Innovation Focus
2.9.9 Customers / End Users
2.9.10 Competitive Positioning
2.9.11 Key Differentiators
2.9.12 Portfolio Matrix
2.9.13 SWOT Analysis
2.9.14 Future Outlook
2.10 Healx Limited
2.10.1 Business Overview
2.10.2 Key Information
2.10.3 Company Focus
2.10.4 Strategic Insights
2.10.5 Strategy Deployed
2.10.6 Product & Service Portfolio
2.10.7 Capability Overview
2.10.8 Technology & Innovation Focus
2.10.9 Customers / End Users
2.10.10 Competitive Positioning
2.10.11 Key Differentiators
2.10.12 Portfolio Matrix
2.10.13 SWOT Analysis
2.10.14 Future Outlook
Companies Mentioned
- InSilico Medicine
- Numerion Labs, Inc.
- BenevolentAI Group
- Shenzhen Jingtai Technology Co., Ltd. (XtalPi)
- Recursion Pharmaceuticals, Inc.
- Deep Genomics Incorporated
- Schrödinger, LLC
- Owkin Inc.
- PeptiDream Inc.
- Healx Limited
